Vanguard Capital Management
VRDN icon

Vanguard Capital Management’s Viridian Therapeutics VRDN Stock Holding History

Vanguard Capital Management’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$84.1M Buy
4,576,860
+409,659
+10% +$6.6M ﹤0.01% 1652
2026
Q1 		$81.5M Buy
+4,167,201
New +$124M ﹤0.01% 1582

Other funds holding VRDN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

Vanguard Capital Management's VRDN Position: Q2 2026 in Review

Vanguard Capital Management increased its Viridian Therapeutics (VRDN) stake by 9.8% in Q2 2026, buying an estimated $6.6M and bringing the position to 4,576,860 shares worth $84.1M. The position accounts for ﹤0.01% of the portfolio, ranked #1652.

Vanguard Capital Management first reported a position in VRDN in Q1 2026 and has held it in 2 quarters since. 213 funds tracked by Wall St. Rank hold VRDN as of Q2 2026.

  • Vanguard Capital Management held 4,576,860 shares of Viridian Therapeutics worth $84.1M as of Q2 2026.
  • Vanguard Capital Management bought 409,659 Viridian Therapeutics shares in Q2 2026, an estimated $6.6M.
  • Viridian Therapeutics made up ﹤0.01% of Vanguard Capital Management's portfolio in Q2 2026, its #1652 holding.
  • Vanguard Capital Management first reported a position in Viridian Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 213 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q2 2026.

Based on Vanguard Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.